Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 6,284 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 6,284 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the sale, the chief financial officer owned 37,592 shares in the company, valued at approximately $472,155.52. The trade was a 14.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Thursday, October 30th, Houte Hans Van sold 3,130 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.80, for a total value of $40,064.00.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded down $0.32 during mid-day trading on Monday, hitting $12.62. 2,124,781 shares of the company traded hands, compared to its average volume of 1,858,191. The firm has a market cap of $970.23 million, a P/E ratio of -4.25 and a beta of 2.30. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $29.56. The firm’s 50 day simple moving average is $9.79 and its 200 day simple moving average is $10.66.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). Nurix Therapeutics had a negative net margin of 292.50% and a negative return on equity of 53.57%. The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $16.06 million. Equities research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NRIX. Tower Research Capital LLC TRC boosted its position in Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after purchasing an additional 3,475 shares during the period. Velan Capital Investment Management LP acquired a new position in Nurix Therapeutics during the 2nd quarter valued at approximately $114,000. E Fund Management Co. Ltd. acquired a new position in Nurix Therapeutics during the 1st quarter valued at approximately $122,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Nurix Therapeutics during the 2nd quarter valued at approximately $141,000. Finally, Sei Investments Co. acquired a new position in Nurix Therapeutics during the 2nd quarter valued at approximately $158,000.

Analyst Upgrades and Downgrades

NRIX has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Monday, October 20th. Stifel Nicolaus set a $33.00 price objective on Nurix Therapeutics in a research note on Friday, October 10th. Morgan Stanley lowered their price objective on Nurix Therapeutics from $16.00 to $15.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 14th. Finally, Piper Sandler lowered their price objective on Nurix Therapeutics from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.73.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.